FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy

NCT02398773 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

99

Enrollment

NIH

Sponsor class

Conditions

HER2/Neu Negative
Progesterone Receptor Negative
Progesterone Receptor Positive
Stage IV Breast Cancer AJCC v6 and v7

Interventions

PROCEDURE: Computed Tomography
DRUG: F-18 16 Alpha-Fluoroestradiol
OTHER: Laboratory Biomarker Analysis
PROCEDURE: Positron Emission Tomography

Sponsor

National Cancer Institute (NCI)